Pharmaceutical

Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease

Johnson & Johnson (J&J) has submitted an sBLA seeking approval from the US FDA for Tremfya (guselkumab) to treat Crohn’s disease.

Jun 22, 2024 - 04:00
Johnson & Johnson seeks FDA approval for Tremfya for Crohn’s disease
Johnson & Johnson (J&J) has submitted an sBLA seeking approval from the US FDA for Tremfya (guselkumab) to treat Crohn’s disease.
Read the original article

Tags:

Previous Article

Emergent to sell US sterile manufacturing facility to Bora

Next Article

Sanofi and Biovac partner to produce polio vaccines in Africa

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

[177Lu]Lu-rhPSMA-10.1 by Blue Earth Therapeutics for Me...

Jul 1, 2023

STAT+: ‘A tug of war’: Europe braces for new legislation with far-reaching impacts on pharma and patients

STAT+: ‘A tug of war’: Europe braces for new legislatio...

Apr 25, 2023

STAT+: What will Novo’s VC do with its influx of cash? Don’t expect obesity investments

STAT+: What will Novo’s VC do with its influx of cash? ...

Sep 28, 2023